Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06357559
Other study ID # OCTA in Myopic CNV
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 30, 2024
Est. completion date December 1, 2024

Study information

Verified date April 2024
Source Sohag University
Contact Ahmed Hamdy
Phone 01287307536
Email fcb9976@Gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..


Description:

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV.. regarding the size , shape , core , margin , Appearance , and activity of CNV..


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 1, 2024
Est. primary completion date September 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Years to 75 Years
Eligibility Inclusion Criteria: - All Patients with High Myopia ( > -6 D or Axial Length > 26.5 mm ) with Fundoscopic Changes Consistent with CNVM , with Clear Media are Subjected to OCTA Exclusion Criteria: - Patients with Treated CNVs , or with other Causes of CNVs including : Neovascular AMD , Idiopathic CNV , Traumatic , Inflammatory , Neoplastic , Degenerative ..

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OCTA
Optical Coherence Tomography Angiography

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

References & Publications (1)

Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018 Mar;63:92-106. doi: 10.1016/j.preteyeres.2017.10.005. Epub 2017 Oct 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA Describing the Choroidal Neovascularization in High Myopic Patients diagnosed by OCTA Regarding its Activity .. 1 year
See also
  Status Clinical Trial Phase
Completed NCT05677685 - VISUPRIME® Eye Drops N/A
Active, not recruiting NCT03797547 - Real Life Study in Myopic Neovascularization
Completed NCT03971162 - Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization N/A
Recruiting NCT05494775 - Effect of Corona Virus on Intravitreal Injections N/A
Suspended NCT04222842 - CM082 in Patients With Myopic Choroidal Neovascularization (CNV) Phase 1